Related Experiment Video
Updated: May 1, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
45.2K
Effects of allopurinol on endothelial dysfunction: a meta-analysis
Mehmet Kanbay1, Dimitrie Siriopol, Ionut Nistor
1Department of Medicine, Division of Nephrology, Istanbul Medeniyet University School of Medicine, Istanbul, Turkey.
American Journal of Nephrology
|April 23, 2014
Summary
Allopurinol treatment significantly improves endothelial-dependent vasodilation in patients with hyperuricemia. However, it does not affect endothelial-independent vasodilation, indicating a specific vascular benefit.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Vascular Biology
Background:
- Endothelial dysfunction is a key factor in cardiovascular disease.
- Allopurinol, a xanthine oxidase inhibitor, is used to treat hyperuricemia.
- Previous studies on allopurinol's effect on endothelial function have yielded inconsistent results due to small sample sizes and varied methodologies.
Purpose of the Study:
- To conduct a meta-analysis evaluating the impact of allopurinol on both endothelial-dependent and endothelial-independent vasodilation.
- To synthesize evidence from existing clinical trials to provide a more robust assessment of allopurinol's vascular effects.
Main Methods:
- A comprehensive literature search was performed across major electronic databases (Medline, PubMed, EMBASE, SCOPUS, EBSCO, Cochrane Library) from 1985 to 2013.
- Included were randomized and non-randomized clinical trials assessing allopurinol's effects on endothelial function.
- Sensitivity analyses were conducted by sequentially excluding studies to assess their impact on pooled treatment effects. Heterogeneity was evaluated using Cochran Q test and I² statistic.
Main Results:
- The meta-analysis included 11 studies (9 randomized, 2 observational) involving 257 patients for endothelial-dependent vasodilation and 73 patients for endothelial-independent vasodilation.
- Allopurinol treatment significantly improved endothelial-dependent vasodilation (mean difference 2.69%, 95% CI 2.49-2.89%, p < 0.001).
- No significant effect of allopurinol was observed on endothelial-independent vasodilation (mean difference -0.08%, 95% CI -0.50-0.34, p = 0.70).
Conclusions:
- Treatment of hyperuricemia with allopurinol is associated with a significant improvement in endothelial-dependent vasodilation.
- Allopurinol does not demonstrate a significant effect on endothelial-independent vasodilation.
- These findings suggest that allopurinol may offer specific benefits for vascular health by improving the function of the endothelium.
Related Concept Videos
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
379
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
400
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
400